PRME Q4 2024 Earnings — Prime Medicine, Inc. Revenue & Financial Results | Market Cap Arena

PRMEPrime Medicine, Inc.

$771M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

$2M100.0% margin

Operating Income

-$44M-2025.7% margin

Net Income

-$42M-1936.6% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

+944.5%

Cash Flow

Operating Cash Flow

$16M

Free Cash Flow

$14M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$298M

Total Liabilities

$144M

Stockholders' Equity

$153M

Cash & Equivalents

$182M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	$2M	$0	—
Operating Income	-$44M	-$68M	+35.0%
Net Income	-$42M	-$66M	+35.6%